Floatz logo

Fasinumab

Osteoarthritis

Regeneron Pharmaceuticalsmonoclonal_antibodyPhase 3Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Osteoarthritis cohort.

Asset / SponsorPhaseRating
Naltrexone
Brigham and Women's Hospital
Phase 4BBB
Buprenorphine
Mundipharma Pte Ltd.
Phase 4BBB
Oxycodone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4BBB
FENTANYL
Janssen Pharmaceutica
Phase 4BBB
Liraglutide
Henrik Gudbergsen
Phase 4BBB

View all 47 →

Same molecule, other indications

Fasinumab is also rated in:

Low Back PainDormant
CCC
Indicative ·
48 / 100
View asset →
sciaticaDormant
CC
Indicative ·
45 / 100
View asset →
dyspepsiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →